Literature DB >> 15004747

[Strong opioids and constipation].

A Schwarzer1, F Nauck, E Klaschik.   

Abstract

In cancer pain therapy treatment with strong opioids is essential. However, it may be accompanied by the occurrence of various adverse effects. The most frequent and persistent side effect in the course of opioid treatment is constipation. It is mainly caused by linkage of the opioid to the peripheral mu-receptors in the bowel and may increase as a result of certain concomitant circumstances, such as poor intake of fluids or electrolyte disorder. Present research indicates that there is a relation between type of opioid and degree of constipation, i.e. treatment with transdermal fentanyl or methadone tends to cause less constipation compared to morphine or hydromorphone. The route of administration of morphine--oral vs. subcutaneous--does not seem to affect the incidence of opioid-induced constipation. Furthermore, prophylaxis and efficient control of opioid-induced constipation still fail to be part of the routine in pain treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15004747     DOI: 10.1007/s00482-004-0325-3

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  41 in total

1.  Cancer pain: an update of pharmacological approaches in pain therapy.

Authors:  Ingrid Gralow
Journal:  Curr Opin Anaesthesiol       Date:  2002-10       Impact factor: 2.706

2.  Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.

Authors:  S Ahmedzai; D Brooks
Journal:  J Pain Symptom Manage       Date:  1997-05       Impact factor: 3.612

3.  Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain.

Authors:  J O Wong; G L Chiu; C J Tsao; C L Chang
Journal:  Acta Anaesthesiol Sin       Date:  1997-03

4.  Low-dose oral naloxone reverses opioid-induced constipation and analgesia.

Authors:  Maywin Liu; Eric Wittbrodt
Journal:  J Pain Symptom Manage       Date:  2002-01       Impact factor: 3.612

5.  Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features.

Authors:  W F Stewart; J N Liberman; R S Sandler; M S Woods; A Stemhagen; E Chee; R B Lipton; C E Farup
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

6.  Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.

Authors:  L Allan; H Hays; N H Jensen; B L de Waroux; M Bolt; R Donald; E Kalso
Journal:  BMJ       Date:  2001-05-12

7.  High-dose tramadol in comparison to low-dose morphine for cancer pain relief.

Authors:  S Grond; L Radbruch; T Meuser; G Loick; R Sabatowski; K A Lehmann
Journal:  J Pain Symptom Manage       Date:  1999-09       Impact factor: 3.612

Review 8.  Constipation--modern laxative therapy.

Authors:  E Klaschik; F Nauck; C Ostgathe
Journal:  Support Care Cancer       Date:  2003-09-20       Impact factor: 3.603

9.  Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.

Authors:  Barbara Donner; Michael Zenz; Michael Tryba; Michael Strumpf
Journal:  Pain       Date:  1996-03       Impact factor: 6.961

10.  The relationship between opioid use and laxative use in terminally ill cancer patients.

Authors:  N P Sykes
Journal:  Palliat Med       Date:  1998-09       Impact factor: 4.762

View more
  4 in total

Review 1.  [Is the pharmacological treatment of constipation in palliative care evidence based? : a systematic literature review].

Authors:  S Bader; M Weber; G Becker
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

Review 2.  [Opioid-induced bowel dysfunction: a literature analysis on pathophysiology and treatment].

Authors:  Jürgen Osterbrink; Ute Haas
Journal:  Wien Med Wochenschr       Date:  2008

Review 3.  [Methylnaltrexone. A new approach for therapy of opioid-induced obstipation].

Authors:  D Chappell; P Conzen
Journal:  Schmerz       Date:  2009-10       Impact factor: 1.107

4.  [Transdermal and oral opioids for outpatient pain therapy. Comparing patients' characteristics by a claims data analysis].

Authors:  A Höer; M Kurepkat; A Gottberg; B Häussler
Journal:  Schmerz       Date:  2008-04       Impact factor: 1.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.